Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ohr Pharmaceutical has gained US and European patients entitled, preparation of a therapeutic composition.
Subscribe to our email newsletter
The patents cover claims related to the chemical structures, sequences of the peptide constituents and method of manufacture of OHR/AVR118.
Ohr Pharmaceutical CEO Irach Taraporewala said the patents strengthen the company’s OHR/AVR118 cancer cachexia program currently being investigated in a Phase II clinical trial.
"OHR/AVR118 has the potential to greatly benefit advanced cancer patients suffering from the debilitating effects of cachexia," Taraporewala added.
"Stronger, more stable patients have a much better chance of tolerating the intense chemotherapies and radiation therapies involved in treating late stages of cancer."
Ohr is a pharmaceutical company focused on the clinical development of new drugs for underserved therapeutic needs in growing markets.